333 related articles for article (PubMed ID: 17347147)
1. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
2. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.
Stork R; Campigna E; Robert B; Müller D; Kontermann RE
J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871
[TBL] [Abstract][Full Text] [Related]
4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
[TBL] [Abstract][Full Text] [Related]
6. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
Stork R; Müller D; Kontermann RE
Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
[TBL] [Abstract][Full Text] [Related]
7. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
9. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
10. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
11. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies.
Stork R; Zettlitz KA; Müller D; Rether M; Hanisch FG; Kontermann RE
J Biol Chem; 2008 Mar; 283(12):7804-12. PubMed ID: 18211902
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.
Asano R; Kuroki Y; Honma S; Akabane M; Watanabe S; Mayuzumi S; Hiyamuta S; Kumagai I; Sode K
MAbs; 2018; 10(6):854-863. PubMed ID: 29985753
[TBL] [Abstract][Full Text] [Related]
13. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
15. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
[TBL] [Abstract][Full Text] [Related]
16. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
[TBL] [Abstract][Full Text] [Related]
17. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
18. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
19. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
[TBL] [Abstract][Full Text] [Related]
20. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
